RECRUITING

Esophageal Cancer Risk Registry

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.

Official Title

Esophageal Cancer Risk Registry

Quick Facts

Study Start:1999-06
Study Completion:2050-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00260585

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Known or suspected esophageal or gastroesophageal junction malignancy
  2. * Known Barrett's metaplasia
  3. * Clinical management of symptomatic gastroesophageal reflux disease (GERD)
  4. * Achalasia
  5. * Hiatal hernia
  1. * Elevated pre-operative bloodwork will not have the additional biopsies taken.
  2. * Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and/or International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.

Contacts and Locations

Study Contact

Julie A Ward, BSN
CONTACT
412-647-8583
wardj@upmc.edu
Judy Forster, BSN
CONTACT
412-647-8579
forsje@upmc.edu

Principal Investigator

James D. Luketich, MD
PRINCIPAL_INVESTIGATOR
Department of Cardiothoracic Surgery

Study Locations (Sites)

Department of Cardiothoracic Surgery
Pittsburgh, Pennsylvania, 15232
United States

Collaborators and Investigators

Sponsor: University of Pittsburgh

  • James D. Luketich, MD, PRINCIPAL_INVESTIGATOR, Department of Cardiothoracic Surgery

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date1999-06
Study Completion Date2050-12

Study Record Updates

Study Start Date1999-06
Study Completion Date2050-12

Terms related to this study

Keywords Provided by Researchers

  • gastroesophageal reflux disease
  • GERD
  • hiatal hernia
  • achalasia
  • Barrett's metaplasia
  • Anti-Reflux Surgery
  • Known/suspected esophageal/gastroesophageal junction tumor
  • Esophageal disorders such as Barrett's metaplasia
  • Symptomatic gastroesophageal reflux disease

Additional Relevant MeSH Terms

  • Esophageal Cancer
  • Gastroesophageal Reflux Disease (GERD)
  • Esophageal Diseases
  • Hiatal Hernia
  • Esophageal Achalasia